Epratuzumab-cys-tesirine

N/A

Report date: 2025/11/25 20:00:09

Base Information

Drug NameEpratuzumab-cys-tesirine
Drug Alias NamehLL2-cys-PBDEpratuzumab-cys-SG3249ADCT-602
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SG3199 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA cross linking agentsAnti-CD22
TargetsDNACD22
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdc Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOverland ADCT BioPharmaAdc Therapeutics SaThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A